These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A full-length 3D structure for MAPK/ERK kinase 2 (MEK2). Liang H; Liu T; Chen F; Liu Z; Liu S Sci China Life Sci; 2011 Apr; 54(4):336-41. PubMed ID: 21509657 [TBL] [Abstract][Full Text] [Related]
3. MEK1/2 dual-specificity protein kinases: structure and regulation. Roskoski R Biochem Biophys Res Commun; 2012 Jan; 417(1):5-10. PubMed ID: 22177953 [TBL] [Abstract][Full Text] [Related]
4. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Fischmann TO; Smith CK; Mayhood TW; Myers JE; Reichert P; Mannarino A; Carr D; Zhu H; Wong J; Yang RS; Le HV; Madison VS Biochemistry; 2009 Mar; 48(12):2661-74. PubMed ID: 19161339 [TBL] [Abstract][Full Text] [Related]
5. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118 [TBL] [Abstract][Full Text] [Related]
6. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2. Piao C; Jin M; Kim HB; Lee SM; Amatya PN; Hyun JW; Chang IY; You HJ Oncogene; 2009 May; 28(21):2173-84. PubMed ID: 19398949 [TBL] [Abstract][Full Text] [Related]
7. Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia. Scholl FA; Dumesic PA; Barragan DI; Harada K; Bissonauth V; Charron J; Khavari PA Dev Cell; 2007 Apr; 12(4):615-29. PubMed ID: 17419998 [TBL] [Abstract][Full Text] [Related]
8. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Catalanotti F; Reyes G; Jesenberger V; Galabova-Kovacs G; de Matos Simoes R; Carugo O; Baccarini M Nat Struct Mol Biol; 2009 Mar; 16(3):294-303. PubMed ID: 19219045 [TBL] [Abstract][Full Text] [Related]
9. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors. Han S; Zhou V; Pan S; Liu Y; Hornsby M; McMullan D; Klock HE; Haugen J; Lesley SA; Gray N; Caldwell J; Gu XJ Bioorg Med Chem Lett; 2005 Dec; 15(24):5467-73. PubMed ID: 16199156 [TBL] [Abstract][Full Text] [Related]
10. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Yeh TC; Marsh V; Bernat BA; Ballard J; Colwell H; Evans RJ; Parry J; Smith D; Brandhuber BJ; Gross S; Marlow A; Hurley B; Lyssikatos J; Lee PA; Winkler JD; Koch K; Wallace E Clin Cancer Res; 2007 Mar; 13(5):1576-83. PubMed ID: 17332304 [TBL] [Abstract][Full Text] [Related]
11. ERK1/2 can feedback-regulate cellular MEK1/2 levels. Hong SK; Wu PK; Karkhanis M; Park JI Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823 [TBL] [Abstract][Full Text] [Related]
12. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway. Adler V; Qu Y; Smith SJ; Izotova L; Pestka S; Kung HF; Lin M; Friedman FK; Chie L; Chung D; Boutjdir M; Pincus MR Biochemistry; 2005 Aug; 44(32):10784-95. PubMed ID: 16086581 [TBL] [Abstract][Full Text] [Related]
13. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763 [TBL] [Abstract][Full Text] [Related]
14. Selective transcriptional down-regulation of human rhinovirus-induced production of CXCL10 from airway epithelial cells via the MEK1 pathway. Zaheer RS; Koetzler R; Holden NS; Wiehler S; Proud D J Immunol; 2009 Apr; 182(8):4854-64. PubMed ID: 19342664 [TBL] [Abstract][Full Text] [Related]
15. MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. Wu PK; Park JI Semin Oncol; 2015 Dec; 42(6):849-62. PubMed ID: 26615130 [TBL] [Abstract][Full Text] [Related]
16. MAP kinase: it's been longer than fifteen minutes. Sturgill TW Biochem Biophys Res Commun; 2008 Jun; 371(1):1-4. PubMed ID: 18406346 [TBL] [Abstract][Full Text] [Related]
17. In silico investigation of new binding pocket for mitogen activated kinase kinase (MEK): Development of new promising inhibitors. Yari H; Ganjalikhany MR; Sadegh H Comput Biol Chem; 2015 Dec; 59 Pt A():185-98. PubMed ID: 26580563 [TBL] [Abstract][Full Text] [Related]
18. MEK1/2 inhibitors in the treatment of gynecologic malignancies. Miller CR; Oliver KE; Farley JH Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059 [TBL] [Abstract][Full Text] [Related]
20. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Caunt CJ; Sale MJ; Smith PD; Cook SJ Nat Rev Cancer; 2015 Oct; 15(10):577-92. PubMed ID: 26399658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]